Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

• Status: Completed
• Trial end date: 2020-04-08

Summary

Explore stem cell collection with or without bortezomib with in-vivo purging in multiple myeloma.

• Phase: Phase 2

Details

• Lead Sponsor: Siddhartha Ganguly; University of Kansas Medical Center
• Treatments: Bortezomib; JM 3100; Lenograstim; Plerixafor; Sargramostim